PT  - JOURNAL ARTICLE
AU  - Nagavarakishore Pillarsetty
AU  - Lukas M. Carter
AU  - Jason S. Lewis
AU  - Thomas Reiner
TI  - Oncology-Inspired Treatment Options for COVID-19
AID  - 10.2967/jnumed.120.249748
DP  - 2020 Dec 01
TA  - Journal of Nuclear Medicine
PG  - 1720--1723
VI  - 61
IP  - 12
4099  - http://jnm.snmjournals.org/content/61/12/1720.short
4100  - http://jnm.snmjournals.org/content/61/12/1720.full
SO  - J Nucl Med2020 Dec 01; 61
AB  - CR3022 is a human antibody that binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we explore the use of CR3022 as a molecularly targeted radiotherapeutic. Methods: CR3022 was labeled with 131I and purified, yielding 131I-CR3022. Using a magnetic bead assay and a recombinant SARS-CoV-2 spike protein fragment, we tested binding of 131I-CR3022 in the presence and absence of CR3022. Results: We conjugated the antibody CR3022 with a purity of more than 98% and a specific activity of more than 292 MBq/mg. Using a bead-based assay, we confirmed that binding of 131I-CR3022 is selective and is significantly reduced in the presence of unlabeled antibody (3.14% ± 0.14% specific uptake and 0.10% ± 0.01% specific uptake, respectively; P < 0.0001). Conclusion: Our results confirm the potential of CR3022 as a molecularly targeted probe for SARS-CoV-2. A labeled version of CR3022 could potentially be used for Auger radiotherapy or noninvasive imaging.